Topic summary

IGF-1 as a surrogate endpoint and its limitations — the long version

Compounds › Secretagogues & GH axis CJC-1295 observational data ipamorelin needs a source Solved Closed

This is a generated summary. It shows the 5 most-liked posts from a topic of 19, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

k.batistaTL220 May 2025#4

The opening post and I disagree about the size of the effect, not about the direction.

What a well-designed human trial of a secretagogue would look like: randomised, placebo-controlled, adequate sample size, IGF-1 as primary outcome, muscle and strength as secondary outcomes, adequate follow-up duration. Very few secretagogue trials meet that description.

The honest answer is that it depends, and here is what it depends on.

22 likes 14mo

dexa_twice_yearlyTL3Regular Solution8 Jun 2025#7

crossover_review, post #3: Agreed on all of that, and I have nothing to add to it. Go to post

Building on post #6 rather than restating it.

IGF-1 is a question about a distribution, not about a value, and treating it as a value is what produces the confident wrong answers.

6 likes in reply to #3 14mo

IMainwaringTL3Regular20 Jun 2025#9

Confirming post #6 from a second method, which matters more than confirming it from a second person.

IGF-1 as a surrogate: it is a better integrated measure than a spot growth hormone level and it is still a surrogate, with all the caveats that come with surrogates. Stable or rising IGF-1 is not the same as "this is working" in any health-related sense.

31 likes 13mo

r.chukwuTL221 Jul 2025#15

n.osei, post #1: On the subject in the title: IGF-1 as a surrogate endpoint and its limitations — the long version Working notes rather than a conclusion. A narrow question about IGF-1, deliberately narrow, because the broad version has been asked here four times and produced four long threads and no answer. One question, stated units, stated method,… Go to post

Answering the question post #11 raises rather than the one it answers.

A mass result for a short peptide is more discriminating than for a long one, because a single residue difference is a larger proportion of the total. That makes identity confirmation genuinely useful here.

A single observation, in a thread that deserves better than single observations.

17 likes in reply to #1 12mo

BramleyTL2Member5 Aug 2025#18

The strongest argument against my own position on IGF-1, stated as well as I can state it, since nobody else has yet.

33 likes 12mo

Read the full topic (19 posts)

This topic was closed 60 days after the last reply. Closing is automatic for quiet topics so that a settled answer does not collect new questions underneath it. If you have a follow-up, open a new topic and link back to this one — that keeps both readable and gives your question its own title.

Suggested topics

Topic	Participants	Replies	Views	Activity
About the Secretagogues & GH axis category Compounds › Secretagogues & GH axis GHRP class CJC-1295 ipamorelin Pinned Wiki Closed Growth-hormone secretagogues and related compounds. Evidence quality here is markedly lower and we say so. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is…	+6	10	1.1k	14mo
Why this subcategory is stricter about sourcing than most Compounds › Secretagogues & GH axis observational data tesamorelin needs a source GHRP class Wiki Asking directly, because I could not find a straight answer: Why this subcategory is stricter about sourcing than most A comparison question rather than a question about one compound. Two things in the same…	+48	52	617	21d
Why pulsatile secretion matters for interpreting secretagogue claims — a second dataset Compounds › Secretagogues & GH axis GHRP class ipamorelin tesamorelin Under review The question in the title: Why pulsatile secretion matters for interpreting secretagogue claims — a second dataset I will give what I have already checked below so nobody repeats it. Posting a small dataset…	+60	64	25k	15mo
IGF-1 as a surrogate endpoint and its limitations Compounds › Secretagogues & GH axis GHRP class needs a source observational data tesamorelin IGF-1 as a surrogate endpoint and its limitations Writing it up because I had to work it out twice and would rather nobody else did. IGF-1, and specifically the version of it that the documentation does not…	+5	9	35k	4mo
CJC-1295 with and without DAC: what the modification does — what changed since Compounds › Secretagogues & GH axis GHRP class observational data CJC-1295 tesamorelin CJC-1295 with and without DAC: what the modification does — what changed since Writing it up because I had to work it out twice and would rather nobody else did. What changes if the standard account of…		4	5.1k	7mo

Related topics — sharing the tags CJC-1295, observational data, ipamorelin

Topic	Participants	Replies	Views	Activity
Contributing data without breaching anyone's privacy Data & Tools › Datasets data table confounding observational data Solved Contributing data without breaching anyone's privacy Writing it up because I had to work it out twice and would rather nobody else did. Asking about contributing data without breaching directly, because I…	+65	71	839	5mo
Revisiting: Oral versus injected administration claims for BPC-157 Compounds › Repair & healing peptides observational data needs a source TB-500 BPC-157 Solved On the subject in the title: Revisiting: Oral versus injected administration claims for BPC-157 Working notes rather than a conclusion. A follow-up question about Oral versus injected administration claims…	+23	27	7.7k	15mo
Reading a preclinical wound-healing model and its relevance to a human tendon — a second dataset Compounds › Repair & healing peptides observational data preprint BPC-157 Reading a preclinical wound-healing model and its relevance to a human tendon — a second dataset — setting out what I have, and where I think it stops being reliable. Posting a small dataset on Reading a…	+64	69	27k	4mo
What would change my mind about repair peptides: a specific answer Compounds › Repair & healing peptides TB-500 needs a source preprint Under review What would change my mind about repair peptides: a specific answer — that is the question, and I have not found it answered plainly anywhere I have looked. Documentation question rather than a pharmacological…	+26	30	1.1k	23h
Research-use-only status: what it means legally and practically — a second dataset Compounds › Other compounds research use only mislabelling needs a source custom synthesis Solved Research-use-only status: what it means legally and practically — a second dataset — setting out what I have, and where I think it stops being reliable. Posting a small dataset on Research-use-only status. It…	+109	125	2k	16mo